Ignite Creation Date:
2025-12-24 @ 9:40 PM
Ignite Modification Date:
2026-01-01 @ 9:06 PM
Study NCT ID:
NCT07122232
Status:
COMPLETED
Last Update Posted:
2025-08-14
First Post:
2025-08-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Comparative Study of Thrombocytopenia in Plasmodium Vivax and Falciparum Malaria
Sponsor:
Rafiullah Hotak
Organization:
Study Overview
Official Title:
Comparative Analysis of Thrombocytopenia in Plasmodium Vivax and Plasmodium Falciparum Malaria: A Prospective Cross-Sectional Study From a Tertiary Care Hospital in Peshawar, Pakistan
Status:
COMPLETED
Status Verified Date:
2025-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aimed to compare platelet count patterns in patients infected with either Plasmodium vivax or Plasmodium falciparum, the two most common malaria species in Pakistan. Thrombocytopenia (low platelet count) is a common complication of malaria and can help in identifying disease severity. We conducted this research at a tertiary care hospital in Peshawar, Pakistan, from April to September 2023. A total of 171 adult patients with confirmed malaria infections were enrolled. We measured their platelet counts at admission, day 3, and day 7, and analyzed the severity and progression of thrombocytopenia. The study found that while P. vivax was more common, P. falciparum was more likely to cause severe thrombocytopenia. Understanding these differences helps healthcare providers identify high-risk patients earlier and manage malaria more effectively. The study was approved by the institutional review board of Lady Reading Hospital, Peshawar.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: